Supplier
Huntington Memorial Hospital, INC.
Huntington Memorial Hospital, INC. was paid $6.49M by Medicaid between Jan 2018 and Nov 2024, across 95 billing codes. Its largest line is 99283, emergency room visit (moderate) — 50% of everything it billed.
33Billing provider infoHUNTINGTON MEMORIAL HOSPITAL, INC.
HUNTINGTON, IN 46750
HUNTINGTON, IN 46750
33aNPI1003821729assigned 07/30/2006
33bProvider typeInstitutional Pharmacy
28Total paid$6.49M
24GClaims120,565
24DCodes billed95
24AFirst – last monthJan 2018 – Nov 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RISSER, STANTON controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,530 | $301K | |
| 2019 | 16,868 | $696K | |
| 2020 | 15,278 | $741K | |
| 2021 | 19,086 | $1.13M | |
| 2022 | 22,962 | $1.67M | |
| 2023 | 18,414 | $1.23M | |
| 2024incomplete | 10,427 | $727K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 50% | 18,357 | 16,283 | $3.23M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 7,266 | 5,990 | $1.01M |
| 41899 | Unlisted procedure, dentoalveolar structures | 6.7% | 214 | 203 | $437K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 4.1% | 2,308 | 741 | $269K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.0% | 3,484 | 2,806 | $192K |
| 71045 | Radiologic examination, chest; single view | 2.7% | 1,395 | 1,150 | $172K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.8% | 645 | 448 | $114K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 543 | 500 | $98K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.3% | 625 | 210 | $83K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 464 | 421 | $69K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.1% | 140 | 84 | $68K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 511 | 136 | $63K |
83 more codes
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 13,679 | $59K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 808 | $55K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,719 | $54K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 149 | $53K |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,095 | $46K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 703 | $43K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,477 | $39K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 377 | $37K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 486 | $35K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 539 | $23K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 336 | $21K |
| 80061 | Lipid panel | <1% | 2,603 | $18K |
| 80076 | <1% | 4,232 | $18K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,736 | $15K |
| 84484 | <1% | 2,105 | $12K | |
| 99221 | <1% | 31 | $10K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 32 | $9K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 271 | $8K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 271 | $8K |
| 99219 | <1% | 16 | $8K | |
| 87660 | <1% | 414 | $8K | |
| 87510 | <1% | 414 | $7K | |
| 87480 | <1% | 414 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,400 | $7K |
| 83690 | <1% | 2,237 | $6K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 133 | $6K |
| 85027 | <1% | 1,709 | $5K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 468 | $5K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 108 | $5K |
| 83735 | <1% | 1,571 | $5K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 14 | $5K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 33 | $4K |
| 81001 | <1% | 2,338 | $4K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 366 | $4K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 48 | $4K |
| 80053 | Comprehensive metabolic panel | <1% | 528 | $4K |
| 99217 | <1% | 16 | $3K | |
| 73630 | <1% | 98 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 165 | $3K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 19 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 55 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13 | $2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 14 | $1K |
| 81025 | <1% | 213 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 270 | $1K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 117 | $1K |
| 87800 | <1% | 32 | $1K | |
| 80320 | <1% | 15 | $1K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 18 | $1K |
| 86850 | <1% | 139 | $840.13 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 43 | $720.89 |
| 85014 | <1% | 167 | $434.72 | |
| 85018 | <1% | 167 | $434.72 | |
| 86901 | <1% | 143 | $368.24 | |
| 86900 | <1% | 140 | $358.78 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 12 | $312.17 |
| 84460 | <1% | 116 | $300.90 | |
| 83880 | <1% | 12 | $274.82 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 25 | $253.28 |
| 86592 | <1% | 71 | $239.62 | |
| 82077 | <1% | 18 | $217.75 | |
| 82150 | <1% | 46 | $193.80 | |
| 86140 | <1% | 27 | $135.48 | |
| 85379 | <1% | 15 | $132.34 | |
| 80051 | <1% | 101 | $121.62 | |
| 85610 | <1% | 69 | $95.82 | |
| 82565 | <1% | 105 | $88.90 | |
| 87081 | <1% | 12 | $80.16 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 42 | $73.71 |
| 82947 | <1% | 28 | $70.56 | |
| 84520 | <1% | 101 | $68.44 | |
| 81003 | <1% | 41 | $60.71 | |
| 84450 | <1% | 12 | $25.02 | |
| A0425 | Ground mileage, per statute mile | <1% | 3,390 | $4.00 |
| A0429 | Emergency ambulance ride, basic life support | 0% | 1,092 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 221 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 111 | $0.00 |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | 0% | 333 | $0.00 |
| A0427 | Emergency ambulance ride, advanced life support | 0% | 548 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 15 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 290 | $0.00 |
| 81514 | 0% | 43 | $0.00 | |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRISSER, STANTON (ACFO)
Parent organizationHUNTINGTON MEMORIAL HOSPITAL, INC.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.